FDA guidance
ABILIFY ASIMTUFII, ARIPIPRAZOLE MONOHYDRATE (EXTENDED-RELEASE, INJECTABLE SUSPENSION…
FDA guidance · issued Mar 11, 2025
Key facts
| Title | ABILIFY ASIMTUFII, ARIPIPRAZOLE MONOHYDRATE (EXTENDED-RELEASE, INJECTABLE SUSPENSION - INTRAMUSCULAR), [OTSUKA PHARMACEUTICAL CO., LTD] |
|---|---|
| Issue date | Mar 11, 2025 |
| Center | Center for Drug Evaluation and Research |
| Regulated product | Drugs |
| Topics | Medication Guide |
| Document on fda.gov | accessdata.fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents